Moreover, the evidence of LXR upregulation of lipogenic enzymes SREBP1c, FASN, and SCD1, and the subsequent promotion of lipogenesis in experimental models, has hampered the clinical use of these agonists, especially in the treatment of MASLD [19]. This evidence concerns the gene SCD and metabolic dysfunction-associated steatotic liver disease.